These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

131 related articles for article (PubMed ID: 22443113)

  • 21. Therapeutic targeting of anaplastic lymphoma kinase in lung cancer: a paradigm for precision cancer medicine.
    Katayama R; Lovly CM; Shaw AT
    Clin Cancer Res; 2015 May; 21(10):2227-35. PubMed ID: 25979929
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Targeted therapy for NSCLC: ALK inhibition.
    Pearson R; Kolesar JM
    J Oncol Pharm Pract; 2012 Jun; 18(2):271-4. PubMed ID: 21844131
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antitumor activity of the selective ALK inhibitor alectinib in models of intracranial metastases.
    Kodama T; Hasegawa M; Takanashi K; Sakurai Y; Kondoh O; Sakamoto H
    Cancer Chemother Pharmacol; 2014 Nov; 74(5):1023-8. PubMed ID: 25205428
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Multiplexed deep sequencing analysis of ALK kinase domain identifies resistance mutations in relapsed patients following crizotinib treatment.
    Huang D; Kim DW; Kotsakis A; Deng S; Lira P; Ho SN; Lee NV; Vizcarra P; Cao JQ; Christensen JG; Kim TM; Sun JM; Ahn JS; Ahn MJ; Park K; Mao M
    Genomics; 2013 Sep; 102(3):157-62. PubMed ID: 23434628
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Paracrine receptor activation by microenvironment triggers bypass survival signals and ALK inhibitor resistance in EML4-ALK lung cancer cells.
    Yamada T; Takeuchi S; Nakade J; Kita K; Nakagawa T; Nanjo S; Nakamura T; Matsumoto K; Soda M; Mano H; Uenaka T; Yano S
    Clin Cancer Res; 2012 Jul; 18(13):3592-602. PubMed ID: 22553343
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Ceritinib for treatment of ALK-rearranged advanced non-small-cell lung cancer.
    Vansteenkiste JF
    Future Oncol; 2014 Oct; 10(12):1925-39. PubMed ID: 24856155
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Anaplastic lymphoma kinase inhibitors in brain metastases from ALK+ non-small cell lung cancer: hitting the target even in the CNS.
    Klempner SJ; Ou SH
    Chin Clin Oncol; 2015 Jun; 4(2):20. PubMed ID: 26112806
    [TBL] [Abstract][Full Text] [Related]  

  • 28. ALK-positive non-small cell lung cancer: mechanisms of resistance and emerging treatment options.
    Steuer CE; Ramalingam SS
    Cancer; 2014 Aug; 120(16):2392-402. PubMed ID: 24853389
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Mechanistic understanding of translational pharmacokinetic-pharmacodynamic relationships in nonclinical tumor models: a case study of orally available novel inhibitors of anaplastic lymphoma kinase.
    Yamazaki S; Lam JL; Zou HY; Wang H; Smeal T; Vicini P
    Drug Metab Dispos; 2015 Jan; 43(1):54-62. PubMed ID: 25349124
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Crizotinib-resistant NPM-ALK mutants confer differential sensitivity to unrelated Alk inhibitors.
    Ceccon M; Mologni L; Bisson W; Scapozza L; Gambacorti-Passerini C
    Mol Cancer Res; 2013 Feb; 11(2):122-32. PubMed ID: 23239810
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Emerging protein kinase inhibitors for non-small cell lung cancer.
    Liu SV; Subramaniam D; Cyriac GC; Abdul-Khalek FJ; Giaccone G
    Expert Opin Emerg Drugs; 2014 Mar; 19(1):51-65. PubMed ID: 24354593
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Anaplastic lymphoma kinase inhibitors as anticancer therapeutics: a patent review.
    Mesaros EF; Ott GR; Dorsey BD
    Expert Opin Ther Pat; 2014 Apr; 24(4):417-42. PubMed ID: 24476492
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Experience in integrating ALK testing and crizotinib into the routine treatment of patients with non-small cell lung cancer.
    Gautschi O; Schefer H; Riklin C; Strobel K; Diebold J
    Onkologie; 2013; 36(6):342-7. PubMed ID: 23774148
    [TBL] [Abstract][Full Text] [Related]  

  • 34. ALK inhibitor crizotinib combined with intrathecal methotrexate treatment for non-small cell lung cancer with leptomeningeal carcinomatosis.
    Ahn HK; Han B; Lee SJ; Lim T; Sun JM; Ahn JS; Ahn MJ; Park K
    Lung Cancer; 2012 May; 76(2):253-4. PubMed ID: 22385925
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Comparison of reverse transcription-polymerase chain reaction, immunohistochemistry, and fluorescence in situ hybridization methodologies for detection of echinoderm microtubule-associated proteinlike 4-anaplastic lymphoma kinase fusion-positive non-small cell lung carcinoma: implications for optimal clinical testing.
    Wallander ML; Geiersbach KB; Tripp SR; Layfield LJ
    Arch Pathol Lab Med; 2012 Jul; 136(7):796-803. PubMed ID: 22742552
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Targeting brain metastases in ALK-rearranged non-small-cell lung cancer.
    Zhang I; Zaorsky NG; Palmer JD; Mehra R; Lu B
    Lancet Oncol; 2015 Oct; 16(13):e510-21. PubMed ID: 26433824
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Crizotinib for EML4-ALK positive lung adenocarcinoma: a hope for the advanced disease? Evaluation of Kwak EL, Bang YJ, Camidge DR, et al. Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer. N Engl J Med 2010;363(18):1693-703.
    Antoniu SA
    Expert Opin Ther Targets; 2011 Mar; 15(3):351-3. PubMed ID: 21208134
    [TBL] [Abstract][Full Text] [Related]  

  • 38. New targets in advanced NSCLC: EML4-ALK.
    Crystal AS; Shaw AT
    Clin Adv Hematol Oncol; 2011 Mar; 9(3):207-14. PubMed ID: 21475126
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Crizotinib: a drug that crystallizes a unique molecular subset of non-small-cell lung cancer.
    Ou SH
    Expert Rev Anticancer Ther; 2012 Feb; 12(2):151-62. PubMed ID: 22316363
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Journey of the ALK-inhibitor CH5424802 to phase II clinical trial.
    Latif M; Saeed A; Kim SH
    Arch Pharm Res; 2013 Sep; 36(9):1051-4. PubMed ID: 23700294
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.